Please ensure Javascript is enabled for purposes of website accessibility

These 2 Soaring Biotech Stocks Are Making the Nasdaq Stronger

By Dan Caplinger – Aug 4, 2021 at 1:10PM

Key Points

  • The Nasdaq is outperforming other indexes on Wednesday.
  • A couple of biotech stocks are pulling their weight in helping boost the Nasdaq.
  • One concentrates on cancer treatment, while the other has high hopes for its COVID-19 vaccine candidate.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Nasdaq Composite is holding up better than its fellow market benchmarks.

Wednesday was generally a down day in the stock market, with major indexes showing losses of as much as 1%. However, the Nasdaq Composite (^IXIC) held up quite well, just barely falling below the unchanged mark as of noon EDT.

Most people think of tech stocks when they consider the Nasdaq. But today, it was the biotech industry that scored some big wins that helped the index outperform its peers. Below, we'll highlight BeyondSpring (BYSI -1.04%) and Novavax (NVAX -2.88%) and their contributions to give the overall Nasdaq a boost.

Hope for a big win against cancer

Shares of BeyondSpring skyrocketed almost 150% as of midday on Wednesday. The clinical-stage biotech company announced extremely encouraging results in a phase 3 trial that had investors excited about the future of a key pipeline candidate treatment.

BeyondSpring has been conducting a phase 3 clinical trial of its cancer therapeutic plinabulin in patients with certain types of non-small cell lung cancer. The company released positive top-line data from the trial, showing that combining plinabulin with the common chemotherapy treatment docetaxel increased overall survival compared to chemotherapy alone. The BeyondSpring drug also met key secondary endpoints, including overall response rates and progression-free survival, as well as reductions in incidents of grade 4 neutropenia.

Medical professional talking to a patient wearing a hair-loss cap.

Image source: Getty Images.

The news comes as a pleasant turnaround for shareholders, who've had to deal with a steady decline in the biotech company's share price since 2017. Sluggish progress forced BeyondSpring to do stock offerings to raise cash in past years, diluting investors and causing some to question its future potential.

Now, investors are hopeful that BeyondSpring will be able to use these study results as the basis for gaining approval from the U.S. Food and Drug Administration (FDA). That won't happen overnight, and investors might need to prepare for another stock offering with the price having skyrocketed. In the long run, though, a successful cancer treatment could be a major win for BeyondSpring.

A big sale for Novavax

Elsewhere, shares of Novavax vaulted higher by nearly 20%. The COVID-19 vaccine developer still hasn't received full approval for its candidate, but that's not stopping buyers from lining up to purchase it in the hope that it will get approved soon.

Novavax signed a new agreement with the European Commission under which the EC will buy up to 200 million doses of its experimental vaccine. The agreement calls for initial shipments of 100 million doses, giving the government body an option to double its purchase through 2023.

Novavax has been optimistic that its vaccine will offer a different way for health officials to protect against COVID-19 infection. The company's candidate is a protein subunit vaccine, which differs from the mRNA vaccines and vector vaccines that have been available in Europe and the U.S. to date.

Nevertheless, until Novavax actually gains approval from the FDA and the European Medicines Agency, none of these agreements will produce any true revenue for the company. That means that even with today's big gain in Novavax shares, there could be even more upside if a favorable determination from regulators comes in the near future.

Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BeyondSpring, Inc. Stock Quote
BeyondSpring, Inc.
BYSI
$0.60 (-1.04%) $0.01
NASDAQ Composite Index (Price Return) Stock Quote
NASDAQ Composite Index (Price Return)
^IXIC
$11,285.32 (%)
Novavax Stock Quote
Novavax
NVAX
$16.54 (-2.88%) $0.49

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.